VOLUME 23 | NUMBER 3 | MARCH 2017 nature medicine r e s o u r c e Ewing sarcoma (EwS) is a developmental cancer defined and diagnosed by the presence of the EWS-FLI1 fusion oncogene 1,2 . Despite this shared molecular basis, the clinical presentation and disease courses of patients with EwS vary [3] [4] [5] . This heterogeneity is not reflected by the genetics of EwS, which is characterized by few somatic mutations 6 and only three genes with recurrent genetic lesions (CDKN2A, STAG2 and TP53) [7] [8] [9] . We hypothesized that the observed clinical heterogeneity might coincide with widespread epigenetic heterogeneity, given that two recent studies established the relevance of epigenetics in EwS by identifying a direct link between the EWS-FLI1 fusion protein and widespread epigenomic reprogramming 10, 11 .
r e s o u r c e Ewing sarcoma (EwS) is a developmental cancer defined and diagnosed by the presence of the EWS-FLI1 fusion oncogene 1,2 . Despite this shared molecular basis, the clinical presentation and disease courses of patients with EwS vary [3] [4] [5] . This heterogeneity is not reflected by the genetics of EwS, which is characterized by few somatic mutations 6 and only three genes with recurrent genetic lesions (CDKN2A, STAG2 and TP53) [7] [8] [9] . We hypothesized that the observed clinical heterogeneity might coincide with widespread epigenetic heterogeneity, given that two recent studies established the relevance of epigenetics in EwS by identifying a direct link between the EWS-FLI1 fusion protein and widespread epigenomic reprogramming 10, 11 .
To characterize epigenetic heterogeneity in EwS, we performed DNA methylation sequencing in a large collection of EwS tumors, many of which had previously undergone whole-genome sequencing 9 . We focused this analysis on DNA methylation as the classic epigenetic mark, which is intricately linked to cancer 12 and well-suited for dissecting tumor heterogeneity 13, 14 . On the basis of the resulting data set, we investigated epigenetic heterogeneity on three levels (Fig. 1a) : (i) Analysis of inter-cancer heterogeneity identified EwSspecific patterns that accurately distinguished EwS tumors from other cell types not expressing EWS-FLI1; (ii) analysis of inter-individual heterogeneity identified DNA methylation signatures that were stronger in some patients than in others, reflecting epigenomic differences between tumors; and (iii) analysis of intra-tumor heterogeneity quantified the variability among single cells within the same tumor.
In contrast to many other cancers, DNA methylation differences between EwS tumors did not uncover discrete subtypes, but instead defined a continuous spectrum along two distinct and biologically interpretable dimensions. Individual tumors differed by the strength of an EWS-FLI1 regulatory signature and along a continuum defined by mesenchymal versus stem cell signatures, which potentially reflects the regulatory state of the cell from which the tumor was originally derived. Together, these two dimensions established an epigenetic disease spectrum underlying EwS, which was partially associated with somatic mutations in STAG2 and TP53. EwS tumors also differed in their intra-tumor heterogeneity, and primary tumors from patients who presented with metastatic disease were more heterogeneous than those of patients with localized disease. In summary, this study provides a comprehensive assessment of DNA methylation heterogeneity in EwS, as well as a resource for studying epigenomic deregulation and tumor heterogeneity in genetically homogeneous cancers.
RESULTS

DNA methylation profiling uncovers a unique and predictive epigenomic signature of Ewing sarcoma
To dissect epigenetic tumor heterogeneity in EwS, we established DNA methylation maps for 140 EwS tumors (Supplementary Table 1) . DNA methylation profiling was performed by using reduced representation bisulfite sequencing (RRBS) 15, 16 , which is an accurate and high-throughput assay for DNA methylation profiling 17 . Data quality was consistently high (Supplementary Fig. 1a -c and Supplementary Table 2) , and genomic coverage included not only CpG islands and promoter regions, but also many CpGs located in distal enhancers, CpG island shores, and other functional elements (http://sheffield2017. computational-epigenetics.org). For assay validation, we performed whole-genome bisulfite sequencing (WGBS) on three representative samples and observed high consistency with the RRBS data ( Supplementary Fig. 1d ). We also profiled 16 EwS cell lines with RRBS, including six low-passage cell lines derived from tumors that were part of our cohort. Finally, given the proposed role of mesenchymal stem cells (MSCs) as a potential cell-of-origin of EwS 18 , we generated RRBS data for 32 primary MSC samples obtained from bone marrow (n = 22), placenta (n = 2), and umbilical cord (n = 8) from patients with EwS and from healthy individuals (Supplementary Table 1) .
On the basis of this data set, we investigated epigenetic heterogeneity between cancers, between patients, and within individual tumors (Fig. 1a) . We compared the EwS tumor profiles to publicly available RRBS data for several other cancers and cell types (Supplementary Table 2 ). Unsupervised visualization using multidimensional scaling separated the EwS samples from all other cancers (Fig. 1b) . To confirm and quantify this observation, we trained a logistic regression classifier on the DNA methylation profiles and found that this classifier could distinguish between EwS tumors and a diverse set of other cell types (Supplementary Table 2 ) with a cross-validated test-set accuracy of 98.6% (Supplementary Fig. 1e ). Focusing on our RRBS data set, we also observed that the MSCs separated by tissueof-origin independently of donor age (Fig. 1c) , whereas the EwS cell lines continued to cluster with the EwS tumors, albeit with a tendency toward the edge. A logistic regression classifier distinguished between EwS tumors and MSCs with 99.4% accuracy (Supplementary Fig. 1f) . Low-passage cell lines most closely resembled those tumors from which they were derived ( Supplementary Fig. 1g ), which highlights that patient-specific DNA methylation characteristics were retained in early-passage EwS cell lines cultured in vitro.
To determine an EwS-specific DNA methylation signature, we compared the EwS tumor profiles to a diverse set of RRBS profiles representing more than 50 different cell types (Supplementary Table 2) . We identified 2,917 CpGs that were specifically hypomethylated in EwS (Fig. 1d) and 1,820 CpGs that were specifically hypermethylated (Fig. 1e) . The EwS-specific hypomethylated CpGs were exclusive to EwS samples and were heavily methylated in essentially all other cell types, whereas the difference was less pronounced for EwSspecific hypermethylated CpGs. We performed region set enrichment analysis with LOLA 19 to test these CpGs for enrichment against the LOLA Core database, which consists of a broad collection of DNaseI hypersensitive elements 20 , chromatin immunoprecipitation sequencing (ChIP-seq) peaks 21, 22 , and other regulatory region sets 23, 24 . EwS-specific hypomethylated CpGs were enriched for EwSspecific enhancers 11 ( Fig. 1d and Supplementary Table 3) , which validates our use of DNA methylation as a marker of epigenomic reprogramming in EwS tumors. EwS-specific hypomethylated CpGs were also enriched for open chromatin in prostate cancer cell lines, which might be explained by the biological similarity between EWS-FLI1 and the prostate-specific TMPRSS2-ERG fusion protein, both of which include an ETS factor as a fusion partner 25 . By contrast, EwS-specific hypermethylated CpGs overlapped with developmental regulators of various lineages, including polycomb-repressed regions in pluripotent stem cells, AP-1 binding sites, and binding sites of various developmental transcription factors ( Fig. 1e and Supplementary Table 3 ). The characteristic DNA methylation profiles of EwS samples are also illustrated by epigenome snapshots of individual loci (Fig. 1f,g ).
Collectively, these results establish a DNA methylation signature that was shared by all EwS tumors, distinguishing them with remarkable sensitivity and specificity from other cell types in our data set. EwS cells are thus marked by a highly characteristic epigenomic state, which we further investigated by ChIP-seq analysis for seven histone marks in three representative tumors (Supplementary Fig. 2 ). DNA methylation levels were consistently anti-correlated with histone H3 lysine 27 acetylation (H3K27ac), a defining mark of active enhancers 26, 27 ( Supplementary Fig. 3a,b) . Furthermore, patient-specific differences in DNA methylation reflected patient-specific differences in H3K27ac, with 65% of the most variable regions showing a Pearson correlation below −0.8 ( Supplementary Fig. 3c ). These results confirm that the observed differences in DNA methylation reflect broader epigenomic differences between patients.
Ewing sarcoma is epigenetically heterogeneous in the absence of discrete disease subtypes To compare inter-individual heterogeneity in different cancer types, we calculated the coefficient of variation (CV, defined as the ratio between s.d. and mean) of DNA methylation levels across the genome, which has been proposed as a measure of global heterogeneity within a DNA methylation data set 28 . EwS fell in the medium-to-high range of CV values that we observed across several cancers and cell types (Fig. 2a) . Specifically, the CV of EwS was on par with that of prostate cancer and chronic lymphocytic leukemia (CLL), two genetically heterogeneous cancers of the elderly (the average age of diagnosis is r e s o u r c e Table 2 ). Bar plots indicate significant overlap of EwS-specific hypomethylated regions with public annotation data, based on LOLA analysis 19 (Supplementary Table 3) . (e) As in d, but focusing on CpGs with higher DNA methylation levels in EwS tumors as compared to the reference profiles. (f) Example of EwS-specific hypomethylation at the CCND1 locus, with substantially lower DNA methylation (and anti-correlated histone H3K27 acetylation) in EwS tumors and EwS cell lines as compared to all reference samples. DNA methylation levels are shown for 50 bins spanning the locus (yellow, high methylation; blue, low methylation; white, no data). H3K27ac profiles include a cross-tissue consensus track from the ENCODE project, as well as ChIP-seq data for an EwS cell line (A673) with inducible knock-down of EWS-FLI1 (EWS-FLI1 high/low) 11 and this study's data for three EwS tumors (tumors 119, 120, and 121). (g) As in f, but focusing on EwS-specific hypermethylation of a putative regulatory region at the GATA2 locus. 66 years for prostate cancer and ~71 years for CLL, as opposed to ~15 years for EwS). This result is unlikely to be biased by differences in sample purity, given that CV values were similar between primary EwS tumors and EwS cell lines grown in vitro (Fig. 2a) , and that there was no correlation between CV contribution and estimated tumor purity among the EwS tumors ( Supplementary Fig. 4a ). EwS tumors r e s o u r c e thus seem to be characterized by substantial epigenetic heterogeneity, which contrasts with the genetic homogeneity of EwS.
To dissect the biological basis of DNA methylation heterogeneity among EwS tumors, we focused on four types of genomic region with previously reported regulatory relevance in EwS (Fig. 2b and  Supplementary Fig. 4b ): (i) EwS-specific DNaseI elements based on DNase-seq data for an EwS cell line (SK-N-MC) 20 ; (ii) EWS-FLI1-correlated enhancers, defined as elements that lose H3K27ac signal upon EWS-FLI1 knockdown 11 ; (iii) EWS-FLI1 binding sites based on ChIP-seq for EWS-FLI1 in an EwS cell line (A673) 25 ; and (iv) EWS-FLI1-anti-correlated enhancers, defined as elements that gain H3K27ac signal upon EWS-FLI1 knockdown 11 . DNA methylation levels were most variable at EwS-specific DNaseI elements and at EWS-FLI1-anticorrelated enhancers (Fig. 2b and Supplementary Fig. 4b,c) . Interindividual differences in DNA methylation in these regions were associated with differences in H3K27ac (Fig. 2c,d) , which indicates that the observed patterns of DNA methylation heterogeneity reflect broader epigenomic variability at Ewing-specific regulatory regions.
We expected the inter-individual differences among EwS tumors to group them into a few distinct and epigenomically defined disease subtypes, as observed for other cancers [29] [30] [31] [32] [33] . To test this hypothesis, we applied various unsupervised clustering methods to our DNA methylation data set. However, none of these methods provided convincing evidence of distinct EwS subtypes, but rather identified broadly distributed patterns reminiscent of a continuous disease spectrum (Fig. 2e) . The absence of any consistent and reproducible disease subtypes in our data set was confirmed by multiple lines of evidence, including coverage-based data filtering, imputation of missing values, use of pairwise shared CpGs, and averaging across tiling regions ( Supplementary Fig. 5 ), and we also did not observe a consistent association between the data set's principal components and various clinical variables (Supplementary Fig. 6 ).
DNA methylation heterogeneity defines an epigenetic disease spectrum in Ewing sarcoma Given widespread inter-individual heterogeneity in the absence of well-defined patient clusters or disease subtypes, we focused once more on the four genomic region sets with regulatory relevance in EwS (introduced in Fig. 2b) , and we analyzed how DNA methylation in these regions varied across samples. Overlaying all regions in each of the sets, we calculated four DNA methylation profiles that aggregate the DNA methylation levels of these regions (Fig. 3a) . Because DNA methylation levels are anti-correlated with transcription factor occupancy and regulatory activity [34] [35] [36] [37] [38] , we used these aggregate DNA methylation profiles to define the 'methylation-based inference of regulatory activity' (MIRA) score as a quantitative measure of the regulatory activity of a given region set in a given sample (Fig. 3b) .
By comparing aggregate DNA methylation profiles and MIRA scores in EwS samples with a diverse set of reference profiles (Supplementary Table 2) , we observed the most striking differences for the first and the last of the four region sets (Fig. 3c) . EwS-specific DNaseI elements showed strong dips and high MIRA scores specifically in EwS tumors and cell lines, indicating the presence of EwS-specific activity at these elements. EWS-FLI1 binding sites and EWS-FLI1-correlated enhancers behaved similarly, although these regions had lower DNA methylation levels in all tissues and a smaller difference in MIRA score between EwS and reference samples. Finally, for EWS-FLI1-anti-correlated enhancers, we observed higher levels of DNA methylation in the EwS samples and MIRA scores that were within the range observed among the reference samples.
Focusing on the EwS-specific DNaseI elements and grouping the reference samples by cell type, only EwS tumors and EwS cell lines had positive MIRA scores (indicative of regulatory activity at these EwSspecific DNaseI elements), whereas all other cell types-including various cancers, primary tissues, and cultured cell lines-had negative MIRA scores (Fig. 3d and Supplementary Fig. 7) . By contrast, plotting the MIRA scores for EWS-FLI1-anti-correlated enhancers (Fig. 3e) placed EwS tumors and EwS cell lines in the middle of a continuous spectrum. On the basis of the RRBS profiles and annotations of the reference samples, we found that this spectrum was marked by mesenchymal cells at one end (high MIRA scores, indicating strong regulatory activity) and pluripotent stem cells at the other end (low MIRA scores, indicating little or no regulatory activity).
Our analysis thus uncovered two biologically informative dimensions underlying the observed DNA methylation heterogeneity in EwS. The first dimension is defined by EwS-specific DNaseI hypersensitive elements and seems to measure the degree to which a tumor's epigenome has been reprogrammed to the characteristic regulatory state of EWS-FLI1 expressing cells (Fig. 3f) . The second dimension, which is defined by EWS-FLI1-anti-correlated enhancers, reflects the relative strength of a mesenchymal differentiation signature as opposed to a signature associated with pluripotent stem cells (Fig. 3g) . When plotted, the scores of individual EwS tumors along these two dimensions cover a continuous spectrum (Fig. 3f,g) , with little correlation between the two (Pearson's r = −0.23; Supplementary Fig. 8a) .
The observed DNA methylation differences along these two dimensions could not be explained as a side effect of technical or biological biases. First, higher tumor purity was positively correlated with higher scores on the Ewing-like dimension mainly because of a few outliers with low tumor purity (r = 0.52 dropping to 0.17 when these samples are removed; Supplementary Fig. 8b) . Second, the mesenchymal dimension was largely uncorrelated with tumor purity (r = −0.26, Supplementary Fig. 8c) . Third, the distribution of EwS cell lines cultured in vitro (which did not have any adjacent tissue) was similar to the EwS tumors (Fig. 3f,g ), which suggests that a sample's position along these two dimensions is a cell-intrinsic property. Fourth, there was no apparent association between tumor location in the body and either of the two dimensions (Supplementary Fig. 8d ). Our results thus establish an epigenetic disease spectrum underlying EwS, defined by 'Ewing-like' and 'mesenchymal versus stem-like' regulatory signatures as its two dimensions.
Ewing sarcoma tumors are characterized by high and variable levels of intra-tumor heterogeneity Having investigated DNA methylation heterogeneity between cancers (Fig. 1) and between individuals (Figs. 2 and 3) , we next focused on DNA methylation differences between individual cells within the same tumor. RRBS provides a powerful tool for dissecting such intratumor heterogeneity, given that DNA methylation is a binary mark, and that each sequencing read captures the DNA methylation status of one allele obtained from one single cell. We used two bioinformatic methods for assessing intra-tumor heterogeneity in EwS: the 'proportion of discordant reads' (PDR) and the 'proportion of sites with intermediate methylation' (PIM).
The PDR score has been proposed as a measure of locally disordered DNA methylation 13 . It is calculated as the proportion of discordant sequencing reads among all RRBS reads that cover at least four CpGs, where discordant reads are defined as those that contain both methylated and unmethylated CpGs, and concordant reads contain only r e s o u r c e methylated or only unmethylated CpGs. High PDR values have been interpreted as an indicator of epigenomic instability in individual cells, which might contribute to clonal evolution 13 . Calculating PDR scores for our data set, we observed that these values were strongly associated with average DNA methylation levels. They were highest in regions with intermediate DNA methylation levels ( Supplementary  Fig. 9a ) and lowest in regions with DNA methylation levels near 0% or near 100% (Supplementary Fig. 9b ). The average PDR score across all EwS tumors was in the same range as those for chondrosarcoma and prostate cancer, but lower than those for acute promyelocytic leukemia, CLL, and glioblastoma (Fig. 4a) .
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To complement and extend these analyses, we investigated intermediate DNA methylation levels as an alternative measure of epigenetic intra-tumor heterogeneity. The PIM score leverages the binary character of DNA methylation: a single allele in a single cell is either 0% or 100% methylated, and intermediate DNA methylation arises from averaging across a heterogeneous population that comprises both methylated and unmethylated alleles of a given CpG. Intermediate DNA methylation levels thus reflect cell-to-cell heterogeneity. We identified CpGs with intermediate DNA methylation levels in a given sample using a Bayesian binomial credibility interval ( Fig. 4b and  Supplementary Fig. 9c ) and calculated PIM scores for each sample. To compare PIM scores between data sets, we controlled for differential CpG coverage by restricting the analysis to shared CpGs in each pair of samples, calculating relative PIM scores as the ratio of pairwise shared CpG sites with intermediate DNA methylation in one sample versus another (Fig. 4b) . All pairwise relative PIM scores for a given sample versus all other samples were averaged, and their sample-specific mean was used as an indicator of the sample's overall level of intra-tumor heterogeneity. We observed high relative PIM scores among the EwS tumors (Fig. 4c) , which places them in a range of intra-tumor heterogeneity similar to that of acute promyelocytic leukemia and CLL, and above that of prostate cancer. There was substantial variability between EwS tumors, in part owing to differences in tumor purity (r = −0.46, corresponding to 21% variance explained), which we statistically corrected for as described below. The more homogeneous EwS cell lines had lower average relative PIM scores than EwS tumors (Wilcoxon P value < 10 −4 ), but even their PIM scores were higher than those of prostate cancer.
Comparing PDR and PIM scores genome-wide, we observed substantial correlation not only across genomic regions (r = 0.76; Fig. 4d ), but also across samples within a given genomic region (median r = 0.51; Supplementary Fig. 9d ), which suggests that these two measures capture related but distinct aspects of intra-tumor heterogeneity. For example, PIM identifies regions with a combination of fully methylated and fully unmethylated reads as heterogeneous, whereas PDR does not; by contrast, PDR identifies regions with consistent and reproducible patterns of methylated and unmethylated CpGs as disordered, whereas PIM considers them homogeneous (Fig. 4d) . One practical advantage of PIM over PDR is that it can assess heterogeneity at any covered CpG, not just those in reads spanning at least four CpGs, which resulted in much higher genomic coverage for PIM ( Supplementary  Fig. 9e ). Regions with high average PDR or PIM among the EwS samples (mean score across samples exceeding 80%) were strongly enriched for intronic as well as intergenic regions, highlighting that intra-tumor heterogeneity is most prevalent outside of gene promoters (Supplementary Fig. 9f,g ). In summary, our analyses identified high and variable levels of intra-tumor heterogeneity in EwS, which were in the same range as those observed for much more genetically heterogeneous cancers.
DNA methylation heterogeneity in EwS can be linked to genetic and clinical data
On the basis of the pronounced differences in epigenetic heterogeneity that we observed among EwS tumors, we explored associations with genetic as well as clinical data. Focusing on the 79 EwS tumors that had whole-genome sequencing data 9 (which allowed us to statistically control for differences in tumor purity), we compared the heterogeneity scores defined above (MIRA, PDR, and PIM) with patient annotations such as age, metastatic status at diagnosis, tumor size, tumor location, relapse status, and genetic lesions for STAG2, TP53, and CDKN2A. After controlling for tumor purity and sex using linear models (Supplementary Fig. 10 ), we identified significant associations between MIRA scores and somatic mutation status, between PDR scores and tumor location, and between PIM scores and metastatic status at diagnosis (Fig. 5a and Supplementary Figs. 11 and 12) .
Comparing 16 tumors with a STAG2 mutation to 63 tumors without such a mutation, we observed significantly lower MIRA scores for EWS-FLI1-anti-correlated enhancers in the STAG2 mutated tumors (Wilcoxon P value < 0.01; Fig. 5b ). This result places the STAG2 mutated tumors in the more stem-like area of the EwS spectrum, which is consistent with recent research showing that cohesin mutants enforce stem cell programs 39 . The deletion of CDKN2A, which is a relatively common genetic lesion in EwS, showed no significant association (Wilcoxon P value > 0.1; Supplementary Fig. 11 ), but among the seven TP53-mutated tumors in our cohort, we observed increased MIRA scores for EwS-specific DNaseI elements; this places TP53 mutants in the more Ewing-like area of the spectrum (Wilcoxon P value < 0.03; Fig. 5c ).
Focusing on intra-tumor heterogeneity, we observed significantly higher PDR scores for tumors whose primary location was in the spine (Wilcoxon P value < 0.02). EwS tumors in the spine also had lower MIRA scores for EWS-FLI1-correlated enhancers and for EwSspecific DNaseI elements (Supplementary Fig. 12 ). However, given that only six tumors with primary location in the spine were included in our data set, there is limited statistical support for such an association between intra-tumor heterogeneity and tumor location.
Finally, we observed a significant association between PIM scores and metastatic status at diagnosis. On average, primary tumors from patients whose disease was already metastatic at diagnosis had higher r e s o u r c e PIM scores (indicating higher intra-tumor heterogeneity) than those observed for patients with localized disease (Wilcoxon P value < 0.03; Fig. 5d) . A logistic regression model predicting metastatic status at diagnosis solely on the basis of PIM score performed significantly better than expected by chance, with an area under curve (AUC) value of 0.66 and a permutation P value below 0.04 (Fig. 5e) .
DISCUSSION
Our study establishes the prevalence and characteristics of epigenetic tumor heterogeneity in EwS on the basis of DNA methylation sequencing and bioinformatic analysis of a large patient cohort. Analyzing DNA methylation patterns across cancer types, we identified patterns of enhancer reprogramming that were shared by all EwS samples. But we also observed substantial epigenetic tumor heterogeneity between patients and within tumors, which stands in stark contrast to the genetic homogeneity of EwS. We and others have previously reported characteristic changes of the epigenome in EWS-FLI1 expressing cells 10, 11 , yet we were surprised to see how unique and predictive the DNA methylation patterns of EwS were in comparison to a broad range of reference samples. Bioinformatic classification based on our DNA methylation data set resulted in test-set accuracies close to 100% for distinguishing EwS samples from various other cell types (including MSCs, a potential cell-of-origin of EwS). Regions that were demethylated in EwS but methylated in other cell types were strongly enriched for EwS-specific DNaseI elements, most of which were located outside of gene promoters and constitute putative enhancer elements. Our data thus support the conceptualization of EwS as an 'enhancer disease, ' with widespread epigenomic reprogramming driven by EWS-FLI1.
Epigenetic heterogeneity between patients with EwS followed unexpected patterns. Rather than identifying a small number of distinct subtypes, as observed for many other cancers [29] [30] [31] [32] [33] , we found that DNA methylation differences in EwS gave rise to a continuous disease spectrum along two dimensions. First, the EWS-FLI1 regulatory signature was stronger in some EwS tumors than in others, and also slightly stronger in cell lines than in tumors. Second, the EwS tumors were broadly scattered across a continuum, with a mesenchymal regulatory signature on one end and a pluripotent stem cell signature on the other end. We speculate that the latter dimension might reflect the differentiation state of the cell-of-origin from which a specific EwS tumor has been derived, whereas the former dimension might reflect the depth and degree with which the epigenome of the cancer cells has been reprogrammed to the characteristic EwS-specific enhancer state.
We also observed substantial epigenetic heterogeneity within individual tumors, which we bioinformatically quantified on the basis of the RRBS data. Primary tumors from patients that were metastatic at diagnosis had higher PIM scores (indicating higher intra-tumor heterogeneity) than tumors of patients with localized disease. This observation is consistent with the emerging view that tumor heterogeneity tends to be higher in patients with more aggressive disease 40 . However, at this stage, we can only speculate whether the observed patterns of epigenetic heterogeneity might have any causal role in EwS (for example, by fueling clonal evolution 41 ) and to what degree the patterns are caused by other regulatory mechanisms, such as EWS-FLI1 binding to the DNA.
Finally, our study describes broadly applicable methods for dissecting epigenetic heterogeneity, which contribute to ongoing research into the biological and medical relevance of tumor heterogeneity 42 . Focusing on DNA methylation as a measure of epigenetic heterogeneity has important advantages, including its correlation with other epigenomic marks and with transcription factor binding (we observed a clear footprint of EWS-FLI1 binding in our DNA methylation maps), high accuracy and robustness of clinical DNA methylation assays 43 , and existing proof of concept that DNA methylation biomarkers can contribute to personalized cancer therapy 44, 45 .
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